Spotlight Innovation Inc (STLT) 0.8000 $STLT
Spotlight Innovation Subsidiary Memcine Pharmaceuticals Signs Lease for Laboratory Facilities at The BioVentures Center Located at The University of Iowa Research Park
Marketwired - Thu Sep 10, 7:01AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Memcine Pharmaceuticals has signed a lease for use of a wet laboratory at the Coralville, IA-based BioVentures Center located at The University of Iowa Research Park. The lease provides for access to additional shared bioscience and translational medical research facilities.
Spotlight Innovation Subsidiary Celtic Biotech Retains Exclusive License for Use of Crotamine as Cancer Imaging, Gene Therapy Technology From Instituto Butantan
Marketwired - Wed Sep 09, 7:02AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech has entered into an exclusive patent license agreement, applicable to North America, with Sao Paulo, Brazil-based Instituto Butantan for the use of Crotamine, a neurotoxin derived from the venom of the South American rattlesnake Crotalus durissus, as a potential imaging agent for cancer and gene therapy delivery vector.
Spotlight Innovation Subsidiary Celtic Biotech Prepares to Start Part 2 of Phase I Intravenous Crotoxin Clinical Study
Marketwired - Mon Aug 24, 7:00AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its subsidiary Celtic Biotech has started preparations to conduct Part 2 of the Phase I clinical study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. Crotoxin is a neurotoxin derived from the venom of the South American rattlesnake Crotalus durissus and is Celtic Biotech's lead drug.
Spotlight Innovation to Present at SeeThruEquity Fall Microcap Investor Conference September 10, 2015
Marketwired - Thu Aug 20, 10:42AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that the Company will be a presenter at the SeeThruEquity Fall Microcap Investor Conference to be held at Convene Grand Central in the heart of midtown Manhattan, New York, NY, on September 10, 2015.
Spotlight Innovation CEO to Speak at BioNetwork West Partnering Summit October 26-28, 2015
Marketwired - Fri Aug 14, 12:09PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its CEO Cristopher Grunewald is a scheduled speaker at the BioNetwork West Partnering Summit to be held at the Ritz-Carlton, Laguna Niguel, CA, October 26th through the 28th, 2015.
Spotlight Innovation Engages DAK Capital to Provide Merger and Acquisition Advisory Services
Marketwired - Thu Jul 16, 12:02PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has engaged Rochelle Park, NJ-based DAK Capital, LLC, to provide strategic investment banking advisory services, including merger and acquisition assistance. DAK Capital, a boutique investment bank, provides a broad spectrum of investment advisory services to its middle market clients. Managing Director Jeffrey M. Gold will act as lead banker.
Spotlight Innovation Subsidiary Celtic Biotech Enters Into Research Agreement With Emory University
Marketwired - Mon Jul 06, 12:43PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its subsidiary Celtic Biotech has entered into a Research Agreement with Atlanta-based Emory University. The Phase I study will be designed and conducted by an Emory University research team with the specific aim of demonstrating that the cell penetrating peptide Crotamine can be made into a suitable radiopharmaceutical for imaging lung cancer tumors with positron emission tomography (PET) in a clinical setting.
Spotlight Innovation Retains DresnerAllenCaron as Its Investor Relations Firm
Marketwired - Thu Jun 18, 10:51AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has retained DresnerAllenCaron as its investor relations firm. DresnerAllenCaron will design and execute investor relations programs to broaden awareness and visibility of Spotlight Innovation within the investment community, and the business and financial media.
Spotlight Innovation Completes Acquisition of Memcine Pharmaceuticals
Marketwired - Mon Jun 08, 9:45AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it completed the acquisition of a majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex(TM) vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response. Memcine Pharmaceuticals has a licensing agreement for its technologies with the University of Iowa.
Spotlight Innovation Subsidiary Celtic Biotech Retains the FreeMind Group to Identify, Prepare, and File for Research and Development Grant Opportunities
Marketwired - Tue Jun 02, 2:31PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that FreeMind Group LLC has been retained by its subsidiary Celtic Biotech Iowa, Inc. to identify grant and contract funding opportunities from such agencies as the National Institutes of Health (NIH), Department of Defense (DoD) and Private Foundations, and to prepare and file grant applications for relevant opportunities. FreeMind Group's expertise in applying for grants and contracts extends throughout every government mechanism as well as private foundations open to funding the life sciences.
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Marketwired - Wed May 20, 11:40AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Spotlight Innovation Becomes Member of Iowa Biotechnology Association
Marketwired - Tue May 12, 12:19PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has become a member of the Iowa Biotechnology Association. The Association was founded to unify Iowa's bioscience industry, academic research institutions and economic development organizations, and to foster a strong business and research climate that attracts and retains bioscience talent, companies and funding.
Spotlight Innovation Closes $2.5 Million Financing
Marketwired - Tue Apr 28, 12:05PM CDT
Spotlight Innovation Inc. (the "Company"
(OTCQB: STLT) announces that it has closed on an unsecured convertible promissory note in the gross principal amount of $2,500,000, exclusive of certain fees. The Note has a maturity date of March 27, 2020, and bears interest at the rate of Prime plus five percent (5%) during the first 36 months, increasing to an interest of Prime plus six percent (6%) for the remaining 24 months. The Note is convertible into shares of common stock of the Company at a price of $1.50 per share.
Spotlight Innovation Completes Private Placement Offering of $500,000
Marketwired - Tue Apr 21, 1:25PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces the completion of a $500,000 private placement offering consisting of shares of common stock and warrants.
Spotlight Innovation Subsidiary Celtic Biotech Product EPISORB Available to Compounding Pharmacy Industry
Marketwired - Mon Apr 06, 12:44PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that the product EPISORB, developed by its subsidiary Celtic Biotech Iowa, Inc., has been registered with the U.S. Food and Drug Administration and has been incorporated into the Pharmacy Benefit Managers (PBM) database referenced by health insurance companies when reimbursing drugs. The product makes use of the attributes of cardiotoxin as a cell penetrating peptide and is intended for distribution through the compounding pharmacy industry.
Spotlight Innovation Enters Into Purchase Agreement With Memcine Pharmaceuticals
Marketwired - Tue Mar 17, 12:50PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that Spotlight Innovation Inc. entered into a Purchase Agreement with Coralville, Iowa-based Memcine Pharmaceuticals, Inc. Pursuant to the agreement, Spotlight Innovation will acquire a majority of the outstanding securities of Memcine Pharmaceuticals. The closing of the transaction is contingent upon several conditions including, but not limited to, completion of due diligence and entry into a shareholder agreement.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Licenses Promising Therapy for Chronic Kidney Disease
Marketwired - Tue Mar 10, 2:46PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD). Animal studies have shown that cardiotoxin has the ability to inhibit the inflammatory immune processes that damage the kidneys, can reduce the level of proteinurea, serum creatinine and urea in chronic neuropathy, and recover renal function and reduce renal injury.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Granted Patent by the U.S. Patent and Trademark Office
Marketwired - Thu Jan 15, 1:22PM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Spotlight Innovation Signs Memorandum of Understanding (MOU) With Black Swan LLC
Marketwired - Tue Jan 06, 10:01AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Spotlight Innovation Announces Change of Transfer Agent
Marketwired - Tue Dec 16, 8:03AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces today that effective December 16, 2014, Spotlight Innovation is replacing Securities Transfer Corporation as the transfer agent and registrar of the securities of the Company.
Spotlight Innovation Subsidiary Memcine Pharmaceuticals Signs Lease for Laboratory Facilities at The BioVentures Center Located at The University of Iowa Research Park
Marketwired - Thu Sep 10, 7:01AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Memcine Pharmaceuticals has signed a lease for use of a wet laboratory at the Coralville, IA-based BioVentures Center located at The University of Iowa Research Park. The lease provides for access to additional shared bioscience and translational medical research facilities.
Spotlight Innovation Subsidiary Celtic Biotech Retains Exclusive License for Use of Crotamine as Cancer Imaging, Gene Therapy Technology From Instituto Butantan
Marketwired - Wed Sep 09, 7:02AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech has entered into an exclusive patent license agreement, applicable to North America, with Sao Paulo, Brazil-based Instituto Butantan for the use of Crotamine, a neurotoxin derived from the venom of the South American rattlesnake Crotalus durissus, as a potential imaging agent for cancer and gene therapy delivery vector.
Spotlight Innovation Subsidiary Celtic Biotech Prepares to Start Part 2 of Phase I Intravenous Crotoxin Clinical Study
Marketwired - Mon Aug 24, 7:00AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its subsidiary Celtic Biotech has started preparations to conduct Part 2 of the Phase I clinical study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. Crotoxin is a neurotoxin derived from the venom of the South American rattlesnake Crotalus durissus and is Celtic Biotech's lead drug.
Spotlight Innovation to Present at SeeThruEquity Fall Microcap Investor Conference September 10, 2015
Marketwired - Thu Aug 20, 10:42AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that the Company will be a presenter at the SeeThruEquity Fall Microcap Investor Conference to be held at Convene Grand Central in the heart of midtown Manhattan, New York, NY, on September 10, 2015.
Spotlight Innovation CEO to Speak at BioNetwork West Partnering Summit October 26-28, 2015
Marketwired - Fri Aug 14, 12:09PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its CEO Cristopher Grunewald is a scheduled speaker at the BioNetwork West Partnering Summit to be held at the Ritz-Carlton, Laguna Niguel, CA, October 26th through the 28th, 2015.
Spotlight Innovation Engages DAK Capital to Provide Merger and Acquisition Advisory Services
Marketwired - Thu Jul 16, 12:02PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has engaged Rochelle Park, NJ-based DAK Capital, LLC, to provide strategic investment banking advisory services, including merger and acquisition assistance. DAK Capital, a boutique investment bank, provides a broad spectrum of investment advisory services to its middle market clients. Managing Director Jeffrey M. Gold will act as lead banker.
Spotlight Innovation Subsidiary Celtic Biotech Enters Into Research Agreement With Emory University
Marketwired - Mon Jul 06, 12:43PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its subsidiary Celtic Biotech has entered into a Research Agreement with Atlanta-based Emory University. The Phase I study will be designed and conducted by an Emory University research team with the specific aim of demonstrating that the cell penetrating peptide Crotamine can be made into a suitable radiopharmaceutical for imaging lung cancer tumors with positron emission tomography (PET) in a clinical setting.
Spotlight Innovation Retains DresnerAllenCaron as Its Investor Relations Firm
Marketwired - Thu Jun 18, 10:51AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has retained DresnerAllenCaron as its investor relations firm. DresnerAllenCaron will design and execute investor relations programs to broaden awareness and visibility of Spotlight Innovation within the investment community, and the business and financial media.
Spotlight Innovation Completes Acquisition of Memcine Pharmaceuticals
Marketwired - Mon Jun 08, 9:45AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it completed the acquisition of a majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex(TM) vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response. Memcine Pharmaceuticals has a licensing agreement for its technologies with the University of Iowa.
Spotlight Innovation Subsidiary Celtic Biotech Retains the FreeMind Group to Identify, Prepare, and File for Research and Development Grant Opportunities
Marketwired - Tue Jun 02, 2:31PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that FreeMind Group LLC has been retained by its subsidiary Celtic Biotech Iowa, Inc. to identify grant and contract funding opportunities from such agencies as the National Institutes of Health (NIH), Department of Defense (DoD) and Private Foundations, and to prepare and file grant applications for relevant opportunities. FreeMind Group's expertise in applying for grants and contracts extends throughout every government mechanism as well as private foundations open to funding the life sciences.
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Marketwired - Wed May 20, 11:40AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Spotlight Innovation Becomes Member of Iowa Biotechnology Association
Marketwired - Tue May 12, 12:19PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has become a member of the Iowa Biotechnology Association. The Association was founded to unify Iowa's bioscience industry, academic research institutions and economic development organizations, and to foster a strong business and research climate that attracts and retains bioscience talent, companies and funding.
Spotlight Innovation Closes $2.5 Million Financing
Marketwired - Tue Apr 28, 12:05PM CDT
Spotlight Innovation Inc. (the "Company"
(OTCQB: STLT) announces that it has closed on an unsecured convertible promissory note in the gross principal amount of $2,500,000, exclusive of certain fees. The Note has a maturity date of March 27, 2020, and bears interest at the rate of Prime plus five percent (5%) during the first 36 months, increasing to an interest of Prime plus six percent (6%) for the remaining 24 months. The Note is convertible into shares of common stock of the Company at a price of $1.50 per share. Spotlight Innovation Completes Private Placement Offering of $500,000
Marketwired - Tue Apr 21, 1:25PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces the completion of a $500,000 private placement offering consisting of shares of common stock and warrants.
Spotlight Innovation Subsidiary Celtic Biotech Product EPISORB Available to Compounding Pharmacy Industry
Marketwired - Mon Apr 06, 12:44PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that the product EPISORB, developed by its subsidiary Celtic Biotech Iowa, Inc., has been registered with the U.S. Food and Drug Administration and has been incorporated into the Pharmacy Benefit Managers (PBM) database referenced by health insurance companies when reimbursing drugs. The product makes use of the attributes of cardiotoxin as a cell penetrating peptide and is intended for distribution through the compounding pharmacy industry.
Spotlight Innovation Enters Into Purchase Agreement With Memcine Pharmaceuticals
Marketwired - Tue Mar 17, 12:50PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that Spotlight Innovation Inc. entered into a Purchase Agreement with Coralville, Iowa-based Memcine Pharmaceuticals, Inc. Pursuant to the agreement, Spotlight Innovation will acquire a majority of the outstanding securities of Memcine Pharmaceuticals. The closing of the transaction is contingent upon several conditions including, but not limited to, completion of due diligence and entry into a shareholder agreement.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Licenses Promising Therapy for Chronic Kidney Disease
Marketwired - Tue Mar 10, 2:46PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD). Animal studies have shown that cardiotoxin has the ability to inhibit the inflammatory immune processes that damage the kidneys, can reduce the level of proteinurea, serum creatinine and urea in chronic neuropathy, and recover renal function and reduce renal injury.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Granted Patent by the U.S. Patent and Trademark Office
Marketwired - Thu Jan 15, 1:22PM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Spotlight Innovation Signs Memorandum of Understanding (MOU) With Black Swan LLC
Marketwired - Tue Jan 06, 10:01AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Spotlight Innovation Announces Change of Transfer Agent
Marketwired - Tue Dec 16, 8:03AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces today that effective December 16, 2014, Spotlight Innovation is replacing Securities Transfer Corporation as the transfer agent and registrar of the securities of the Company.
